BACKGROUND: There is increasing evidence showing that extracellular nucleosides [corrected] may be important mediators of vascular inflammation. Nucleoside [corrected] triphosphate diphosphohydrolase-1 (NTPDase-1, identical to CD39), the major vascular endothelial ectonucleotidase, is responsible for the hydrolysis of both extracellular ATP and ADP in the blood plasma to AMP. Studies were therefore conducted to evaluate the role of vascular NTPDase-1/cd39 in modulating platelet activation and vascular injury in cardiac xenografts. MATERIALS AND METHODS: Cardiac xenografts from both wild-type and cd39 knockout mice (C57BL/6 x 129 Svj) were transplanted into Lewis rats. Alterations in cd39 mRNA transcripts and NTPDase activity expression were evaluated in wild-type grafts in untreated rats and then following complement depletion and immunosuppression. Rejection responses were studied with both mutant and wild-type grafts in the following models: presensitization with or without complement depletion, complement depletion alone, and with chronic immunosuppression to induce long-term graft survival. RESULTS: NTPDase biochemical activity in wild-type xenografts rapidly decreased after transplantation but soon rebounded with graft survival. Elevated levels of cd39 mRNA with associated increases in NTPDase activity were observed in all long-term surviving wild-type grafts. Hyperacute xenograft rejection times were comparable in wild-type and mutant grafts but cd39-deficient grafts were subject to more rapid rejection and exhibited pronounced vascular injury in complement-depleted, presensitized rats. The cd39-deficient grafts in immunosuppressed recipients were subject to increased intravascular platelet sequestration and fibrin deposition; this resulted in focal myocardial infarction in long-term surviving mutant xenografts. CONCLUSIONS: Augmentation of NTPDase-1 activity may be an important adaptive response for graft survival. Our results suggest that NTPDase-1/cd39 influences pathways of vascular injury in cardiac xenografts.
BACKGROUND: There is increasing evidence showing that extracellular nucleosides [corrected] may be important mediators of vascular inflammation. Nucleoside [corrected] triphosphate diphosphohydrolase-1 (NTPDase-1, identical to CD39), the major vascular endothelial ectonucleotidase, is responsible for the hydrolysis of both extracellular ATP and ADP in the blood plasma to AMP. Studies were therefore conducted to evaluate the role of vascular NTPDase-1/cd39 in modulating platelet activation and vascular injury in cardiac xenografts. MATERIALS AND METHODS: Cardiac xenografts from both wild-type and cd39 knockout mice (C57BL/6 x 129 Svj) were transplanted into Lewis rats. Alterations in cd39 mRNA transcripts and NTPDase activity expression were evaluated in wild-type grafts in untreated rats and then following complement depletion and immunosuppression. Rejection responses were studied with both mutant and wild-type grafts in the following models: presensitization with or without complement depletion, complement depletion alone, and with chronic immunosuppression to induce long-term graft survival. RESULTS: NTPDase biochemical activity in wild-type xenografts rapidly decreased after transplantation but soon rebounded with graft survival. Elevated levels of cd39 mRNA with associated increases in NTPDase activity were observed in all long-term surviving wild-type grafts. Hyperacute xenograft rejection times were comparable in wild-type and mutant grafts but cd39-deficient grafts were subject to more rapid rejection and exhibited pronounced vascular injury in complement-depleted, presensitized rats. The cd39-deficient grafts in immunosuppressed recipients were subject to increased intravascular platelet sequestration and fibrin deposition; this resulted in focal myocardial infarction in long-term surviving mutant xenografts. CONCLUSIONS: Augmentation of NTPDase-1 activity may be an important adaptive response for graft survival. Our results suggest that NTPDase-1/cd39 influences pathways of vascular injury in cardiac xenografts.
Authors: F H Bach; S C Robson; C Ferran; H Winkler; M T Millan; K M Stuhlmeier; B Vanhove; M L Blakely; W J van der Werf; E Hofer; R de Martin; W W Hancock Journal: Immunol Rev Date: 1994-10 Impact factor: 12.988
Authors: C R Maliszewski; G J Delespesse; M A Schoenborn; R J Armitage; W C Fanslow; T Nakajima; E Baker; G R Sutherland; K Poindexter; C Birks Journal: J Immunol Date: 1994-10-15 Impact factor: 5.422
Authors: Maithili Sashindranath; Karen M Dwyer; Shala Dezfouli; Carly Selan; Sandra Crikis; Bo Lu; Yuping Yuan; Michael J Hickey; Karlheinz Peter; Simon C Robson; Peter J Cowan; Harshal H Nandurkar Journal: Purinergic Signal Date: 2017-03-25 Impact factor: 3.765
Authors: Xiaofeng Sun; Masato Imai; Martina Nowak-Machen; Olaf Guckelberger; Keiichi Enjyoji; Yan Wu; Zain Khalpey; Pascal Berberat; Jeeva Munasinghe; Simon Christopher Robson Journal: Purinergic Signal Date: 2011-06-09 Impact factor: 3.765
Authors: Holger K Eltzschig; David Köhler; Tobias Eckle; Tianqing Kong; Simon C Robson; Sean P Colgan Journal: Blood Date: 2008-09-23 Impact factor: 22.113
Authors: Karen M Dwyer; Simon C Robson; Harshal H Nandurkar; Duncan J Campbell; Hilton Gock; Lisa J Murray-Segal; Nella Fisicaro; Tharun B Mysore; Elzbieta Kaczmarek; Peter J Cowan; Anthony J F d'Apice Journal: J Clin Invest Date: 2004-05 Impact factor: 14.808
Authors: K Koziak; M Bojakowska; S C Robson; K Bojakowski; J Soin; E Csizmadia; P Religa; Z Gaciong; E Kaczmarek Journal: J Thromb Haemost Date: 2008-07-01 Impact factor: 5.824